Resolution Therapeutics appoints Lucy Singah as Chief Financial Officer and Daniel Kennedy as Chief Business Officer
- Highly experienced Chief Financial Officer set to drive corporate and strategic goals of Resolution.
- Accomplished Chief Business Officer will drive business development and partnering deals.
- Appointments follow the announcement of the first patient dosed and safety cleared in its Phase I/II EMERALD study.
Edinburgh and London, UK 10 September 2025 – Resolution Therapeutics (“Resolution” or “Company”), a clinical-stage biopharmaceutical company focused on pioneering novel regenerative macrophage therapies to treat inflammatory and fibrotic diseases, today announces the appointment of Lucy Singah as Chief Financial Officer (CFO) and Daniel Kennedy as Chief Business Officer (CBO).
